FROM FIRST CHECK TO FULL STACK, INSIDE THE DEAL THAT TURNED A BIOTECH BET INTO A $1B PLATFORM

The discussion revolves around the evolution of biotech with AI and venture capital's role. H.P. Goldfield introduces Dr. Dennis Berry of Cathay Innovation and Dr. Thomas Closel, CEO of Alkan. Dennis highlights Cathay's global presence and AI fund, while Thomas explains Alkan's mission to understand biology through AI. They discuss how AI shortens drug discovery, challenging traditional pharma models. Thomas argues that future drug discovery will be AGI-native, contrasting with legacy pharma. Dennis believes AI will revolutionize drug creation, clinical trials, and business models. Thomas is critical of the slow transformation of pharma due to cultural and structural issues. The discussion also touches on the potential impact of quantum computing and the challenges of integrating tech and biotech cultures. They conclude with their reasons for being in Saudi Arabia, emphasizing the ambition and focus on healthcare.